Efficacy and Safety of Oxybutynin Transdermal System in Spinal Cord Injury Patients With Neurogenic Detrusor Overactivity and Incontinence: An Open-label, Dose-titration Study

Urology

Volumn 74, Issue 4, 2009, Pages 741-745

  Kennelly, Michael J ^a   Lemack, Gary E ^b   Foote, Jenelle E ^c   Trop, Cynthia S ^d  

^a Carolinas Rehabilitation   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SHEPHERD CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN;

ABNORMAL VISION; ADULT; APPLICATION SITE REACTION; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERHIDROSIS; INTERMITTENT CATHETERIZATION; MALE; MULTICENTER STUDY; NEUROGENIC BLADDER; NEUROGENIC DETRUSOR OVERACTIVITY; OVERACTIVE BLADDER; PRIORITY JOURNAL; RESIDUAL URINE; SPINAL CORD INJURY; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; SPINAL CORD INJURIES; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; YOUNG ADULT;

EID: 70349462940     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.05.008     Document Type: Article

References (25)

1. Abrams P., Cardozo L., Fall M., et al., Standardisation Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
2. Kaplan S.A., Chancellor M.B., and Blaivas J.G. Bladder and sphincter behavior in patients with spinal cord lesions. J Urol 146 (1991) 113-117
3. Light J.K., and Beric A. Detrusor function in suprasacral spinal cord injuries. J Urol 148 (1992) 355-358
4. Weld K.J., and Dmochowski R.R. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 55 (2000) 490-494
5. Samson G., and Cardenas D.D. Neurogenic bladder in spinal cord injury. Phys Med Rehabil Clin N Am 18 (2007) 255-274
6. Tai C., Roppolo J.R., and de Groat W.C. Spinal reflex control of micturition after spinal cord injury. Restor Neurol Neurosci 24 (2006) 69-78
7. Weld K.J., and Dmochowski R.R. Effect of bladder management on urological complications in spinal cord injured patients. J Urol 163 (2000) 768-772
8. Ethans K.D., Nance P.W., Bard R.J., et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 27 (2004) 214-218
9. O'Leary M., Erickson J.R., Smith C.P., et al. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 26 (2003) 159-162
10. Madersbacher H., Stöhrer M., Richter R., et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicenter trial in the treatment of detrusor hyperreflexia. Br J Urol 75 (1995) 452-456
11. Reitz A., and Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord 42 (2004) 267-272
12. Davila G.W., Daugherty C.A., Sanders S.W., and Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 166 (2001) 140-145
13. Weese D.L., Roskamp D.A., Leach G.E., et al. Intravesical oxybutynin chloride: experience with 42 patients. Urology 41 (1993) 527-530
14. Wan J., and Rickman C. The durability of intravesical oxybutynin solutions over time. J Urol 178 (2007) 1768-1770
15. Oxytrol [prescribing information] (2006), Watson Pharma Inc, Corona, CA
16. Ditropan [prescribing information] (2008), Sanofi-aventis US LLC, Kansas City, MO
17. Ditropan XL [prescribing information] (2004), ALZA Corporation, Mountain View, CA
18. Appell R.A., Chancellor M.B., Zobrist R.H., et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 78 (2003) 696-702
19. Zobrist R.H., Schmid B., Feick A., et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharmacol Res 18 (2001) 1029-1034
20. Dmochowski R.R., Davila G.W., Zinner N.R., et al., Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 168 (2002) 580-586
21. Dmochowski R.R., Sand P.K., Zinner N.R., et al., Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62 (2003) 237-242
22. Dmochowski R.R., Nitti V., Staskin D., et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 23 (2005) 263-270
23. Sand P., Zinner N., Newman D., et al. Oxybutynin transdermal system improves quality of life in adults with overactive bladder: a multicenter, community-based, randomized study. BJU Int 99 (2007) 836-844
24. Marino R.J., Barros T., Biering-Sorensen F., et al., ASIA Neurological Standards Committee 2002. International standards for neurological classification of spinal cord injury. J Spinal Cord Med 26 (2003) S50-S56
25. Finney S.M., Andersson K.E., Gillespie J.L., et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. BJU Int 98 (2006) 503-507